Company Description
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally.
The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products.
The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression.
This segment also includes the development and clinical testing of LivaNova’s aura6000 system for treating obstructive sleep apnea.
It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers.
The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors.
LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 1987 |
| IPO Date | Feb 10, 1993 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 3,300 |
| CEO | Vladimir Makatsaria |
Contact Details
Address: 20 Eastbourne Terrace London, W2 6LG United Kingdom | |
| Phone | 44 20 3325 0660 |
| Website | livanova.com |
Stock Details
| Ticker Symbol | LIVN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001639691 |
| CUSIP Number | G5509L101 |
| ISIN Number | GB00BYMT0J19 |
| Employer ID | 98-1268150 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Vladimir A. Makatsaria | Chief Executive Officer and Director |
| Alex Shvartsburg C.M.A. | Chief Financial Officer |
| Natalia Kozmina | Chief Human Resources Officer |
| Ahmet Tezel Ph.D. | Chief Innovation Officer |
| Lindsey Little | Vice President and Chief Accounting Officer |
| Briana Gotlin | Vice President of Investor Relations |
| Deanna Wilke | Vice President of Corporate Communications |
| Philip Kowalczyk | Chief Strategy and Corporate Development Officer |
| Paul R. Buckman | President of Advanced Circulatory Support and GM of Transcatheter Mitral Valve Replacement |
| Stephanie Bolton | President of Global Epilepsy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 26, 2026 | 144 | Filing |
| May 6, 2026 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| May 6, 2026 | 10-Q | Quarterly Report |
| May 6, 2026 | 8-K | Current Report |
| Apr 30, 2026 | SCHEDULE 13G/A | Filing |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Feb 25, 2026 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Feb 25, 2026 | 10-K | Annual Report |